These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39388913)

  • 1. Efficacy and safety of an ultra-low-dose 0.005 % estriol vaginal gel in the prevention of urinary tract infections in postmenopausal women with genitourinary syndrome of menopause: A randomized double-blind placebo-controlled trial.
    Muiños Fernández N; Martínez Salamanca JI; Pardo González de Quevedo JI; Diz Morales MP; Palomo Alameda L; Duce Tello S; González Béjar M; Rabanal Carrera A; Rosado Martín J; Noguera Vera L; Doyle Sanchez A; Rodríguez Mariblanca A; García Aguilar E
    Maturitas; 2024 Sep; 190():108128. PubMed ID: 39388913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.
    Raz R; Stamm WE
    N Engl J Med; 1993 Sep; 329(11):753-6. PubMed ID: 8350884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
    Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
    Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
    Matarazzo MG; Caruso S; Giunta G; Valenti G; Sarpietro G; Cianci A
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():75-79. PubMed ID: 29367168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
    Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
    Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
    Sánchez-Rovira P; Hirschberg AL; Gil-Gil M; Bermejo-De Las Heras B; Nieto-Magro C
    Oncologist; 2020 Dec; 25(12):e1846-1854. PubMed ID: 32459035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving management of the genitourinary syndrome of menopause: evaluation of a health system-based, cluster-randomized intervention.
    Vesco KK; Leo MC; Bulkley JE; Beadle KR; Stoneburner AB; Francisco M; Clark AL
    Am J Obstet Gynecol; 2021 Jan; 224(1):62.e1-62.e13. PubMed ID: 32693097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of vaginal estriol on urogenital symptoms in postmenopausal women].
    Hejlová P; Zivný J
    Ceska Gynekol; 2004 Jul; 69(4):329-35. PubMed ID: 15369256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
    Caruso S; Cianci S; Amore FF; Ventura B; Bambili E; Spadola S; Cianci A
    Menopause; 2016 Jan; 23(1):47-54. PubMed ID: 26079974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
    Stute P
    Arch Gynecol Obstet; 2013 Dec; 288(6):1199-201. PubMed ID: 24178484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
    Villa P; Tagliaferri V; Amar ID; Cipolla C; Ingravalle F; Scambia G; Ricciardi W; Lanzone A
    Gynecol Endocrinol; 2020 Jun; 36(6):535-539. PubMed ID: 31847628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.
    Dessole S; Rubattu G; Ambrosini G; Gallo O; Capobianco G; Cherchi PL; Marci R; Cosmi E
    Menopause; 2004; 11(1):49-56. PubMed ID: 14716182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of Pueraria mirifica gel and of placebo gel on the vaginal microenvironment of postmenopausal women with Genitourinary Syndrome of Menopause (GSM).
    Sritonchai C; Manonai J; Sophonsritsuk A; Cherdshewasart W
    Maturitas; 2020 Oct; 140():49-54. PubMed ID: 32972635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women.
    Raz R; Colodner R; Rohana Y; Battino S; Rottensterich E; Wasser I; Stamm W
    Clin Infect Dis; 2003 Jun; 36(11):1362-8. PubMed ID: 12766829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Topical Interventions on the Vaginal Microbiota and Metabolome in Postmenopausal Women: A Secondary Analysis of a Randomized Clinical Trial.
    Srinivasan S; Hua X; Wu MC; Proll S; Valint DJ; Reed SD; Guthrie KA; LaCroix AZ; Larson JC; Pepin R; Bhasin S; Raftery D; Fredricks DN; Mitchell CM
    JAMA Netw Open; 2022 Mar; 5(3):e225032. PubMed ID: 35353163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse.
    Rahn DD; Richter HE; Sung VW; Hynan LS; Pruszynski JE
    Am J Obstet Gynecol; 2023 Sep; 229(3):309.e1-309.e10. PubMed ID: 37244454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol.
    Griesser H; Skonietzki S; Fischer T; Fielder K; Suesskind M
    Maturitas; 2012 Apr; 71(4):360-8. PubMed ID: 22285095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.
    Alvisi S; Lami A; Baldassarre M; Lenzi J; Mancini I; Seracchioli R; Meriggiola MC
    J Sex Med; 2022 May; 19(5):761-770. PubMed ID: 35370104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Local Estrogen on the Urogenital Microbiome in Genitourinary Syndrome of Menopause: A Randomized-Controlled Trial.
    Lillemon JN; Karstens L; Nardos R; Garg B; Boniface ER; Gregory WT
    Female Pelvic Med Reconstr Surg; 2022 Jun; 28(6):e157-e162. PubMed ID: 35420551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.